Valerio Therapeutics Reports its Half-Year 2023 Financial Results and Provides an Update on its Activities
New identity unveiled, with the aim at developing innovative therapies against cancer R&D efforts maintained for VIO-01 (formerly OX425) […]
search
Onxeo changes its name and becomes Valerio Therapeutics following approval by the Annual General Meeting of June 6, 2023
All the resolutions approved by the Board of Directors were adopted Paris (France), June 6, 2023 – 6:30 pm […]
Combined General Meeting of June 6, 2023: availability of preparatory documents and participation & voting procedures
Paris (France), May 16, 2023 – 06:00 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX), a clinical-stage biotechnology company […]
Publication of the 2022 Annual Financial Report
Paris (France), April 28, 2023 – 9.00 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX), hereafter “Onxeo” or the […]
Onxeo Reports Full Year 2022 Financial Results and Provides Clinical Development Updates
Phase 1b/2 trial of AsiDNATM in combination with olaparib in the United States in recurrent ovarian, breast and metastatic castration-resistant […]
Onxeo will publish its full-year results on April 24, 2023
Paris (France), April 21, 2023 – 8:30 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX), a clinical-stage biotechnology company […]
Onxeo will publish its full-year results on April 14, 2023
The annual general meeting will be held on June 6, 2023 Paris (France), March 14, 2023 – 6:00 pm […]
Onxeo will publish its full-year results on April 21, 2023
Paris (France), April 14, 2023 – 5:35 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX), a clinical-stage biotechnology company […]
Onxeo: report on the Extraordinary General Meeting of February 6, 2023
Paris (France), February 6, 2023 – 7:30 pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX), (“Onxeo” or “the Company”), […]
Onxeo Announces its Financial Agenda for 2023
Paris (France), January 27, 2023 – 6:00 pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX), (“Onxeo” or “the Company”), […]
ONXEO provides update on the Development Program for its first-in-class drug candidate AsiDNATM
Phase 1b/2 trial of AsiDNATM in combination with olaparib initiated in the United States in recurrent ovarian, breast and metastatic […]
Onxeo advances its second lead candidate OX425 for the treatment of solid tumors
OX425 is a novel DDR Decoy Agonist which also mediates multiple immunostimulatory effects, making it a promising candidate for combination […]
Onxeo Reports its Half-Year 2022 Financial Results and Provides an Update on its Activities
Refocusing R&D efforts as well as accelerating preclinical and clinical programs globally Cash position of €26.9 million as of June […]
High-Grade Glioma Relapse in Children: Onxeo announces the enrollment of the first patient in the phase 1b/2 clinical study conducted by the European ITCC consortium and sponsored by Institut Curie
Paris (France), September 1st, 2022 – 8 pm CEST – Onxeo S.A. (Euronext Growth: ALONX, Nasdaq First North[1]: ONXEO), a […]
Onxeo announces that Nasdaq approved the delisting of its shares from the First North Growth market in Copenhagen
Last day of trading on the First North Growth market on November 8, 2022 Listing on Euronext Growth Paris remains […]
Combined General Meeting of August 17, 2022: Onxeo shareholders approve withdrawal from the Nasdaq First North market in Copenhagen
Company to submit delisting request to Nasdaq Paris (France), August 17, 2022 – 08:00 pm CEST – Onxeo S.A. […]
Combined General Meeting of August 17, 2022: availability of preparatory documents and participation & voting procedures
Paris (France), July 29, 2022 – 06:30 pm CEST – Onxeo S.A. (Euronext Growth: ALONX, Nasdaq First North: ONXEO), a […]
Onxeo announces a Combined General Meeting on August 17, 2022
Paris (France), July 12, 2022 – 07:00 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: […]
Initial IND application for AsiDNA Granted “Study May Proceed” by the U.S. FDA
Onxeo to initiate its first phase 1b/2 trial in the United States in patients with solid tumors Paris (France), […]
Onxeo: Proceedings of the Combined Shareholders’ Meeting of June 15, 2022
All resolutions voted in accordance with Board of Directors’ recommendations Khalil Barrage, Managing Director of Invus’ public equity investments division, […]
Le Journal des Biotechs | Interview of Shefali Agarwal, President and CEO of Onxeo
Watch the interview (in French)
Publication of the 2021 Annual Financial Report
Paris (France), April 28, 2022 – 6.00 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: […]
Onxeo Appoints Dr. Shefali Agarwal as President and Chief Executive Officer
Agarwal is Currently Chairwoman of Onxeo’s Board, a Position Held Since June 2021 Company Outlines Development Strategy Plans Including Preparation […]
Onxeo Reports its Full-Year 2021 Financial Results and announces additional financing of €12 million
Cash position of €17.9 million as of December 31, 2021 Additional financing of €12 million subscribed by historical shareholders Invus […]
Onxeo to present new preclinical data highlighting AsiDNA™’s ability to fight tumor resistance and protect from anticancer treatment toxicity at AACR Annual Meeting 2022
AsiDNA™ proven to overcome resistance to tyrosine kinase inhibitors in lung cancer models AsiDNA™ proven to protect healthy cells when […]
Onxeo appoints Julien Miara as new interim CEO
Paris (France), January 3rd, 2022 – 6:00 pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), (“Onxeo” or “the Company”), […]
Onxeo Announces its Financial Agenda for 2022
Paris (France), January 13, 2022 – 6 pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), […]
Onxeo’s new preclinical data confirm the relevance of combining AsiDNA™ with PARP inhibitors in treating homologous recombination proficient tumors
These pioneering data were presented at ESMO Targeted Anticancer Therapies Congress 2022 Paris (France), March 9, 2022 – 7:00 […]
New preclinical data confirm the ability of AsiDNA™ to tackle the drug-tolerant persister cells and prevent tumor resistance in several combination treatments
These pioneering data were highlighted at the EACR-AstraZeneca Virtual Conference during two dedicated sessions Paris (France), December 8, 2021 […]
Onxeo Continues to Strengthen its Board of Directors
Bryan Giraudo, COO & CFO of U.S. biopharmaceutical company Gossamer Bio, joins the Company’s Board as independent member Paris […]
Onxeo Further strengthens its Board of Directors with two Seasoned Personalities from the Healthcare Sector
Dr Robert L. Coleman, Chief Scientific Officer of US Oncology Network and Dr Jacques Mallet, former SVP Portfolio Analytics/Corporate Strategy […]
Onxeo Reports its 2021 Half-Yearly Financial Results and Provides an Update on its Activities
Cash position of €24.5 million as of June 30, 2021, providing financial visibility until the end of 2022 and enabling […]
Onxeo Announces the Appointment of Dr. Shefali Agarwal as the Company’s Chairwoman of the Board
Danièle Guyot-Caparros, outgoing Chairwoman, remains an independent member of the Board of Directors and Chair of the Audit Committee […]
Onxeo: Report on the Combined General Meeting of June 10, 2021
All resolutions voted in accordance with Board of Directors’ recommendations Shefali Agarwal, MD, a clinical development expert in oncology, is […]
Onxeo Receives Notice of Allowance for a New Patent Broadening the Protection of AsiDNA™ in combination with a PARP Inhibitor in the United States
This new patent protects both AsiDNA™ in combination with a PARP inhibitor and the use of the combination for the […]
Onxeo Announces Formation of Scientific Advisory Committee of Leading Independent Experts
This newly formed committee of international specialists will advise on the scientific and clinical aspects related to the development of […]
Onxeo’s Combined General Meeting on June 10, 2021 in camera: availability of preparatory documents and live webcast login information
Paris (France), May 21, 2021 – 5:45 p.m. CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo”, […]
Onxeo announces the success of its Rights Issue with €9.7 million raised
This transaction will accelerate the development of the Company and its portfolio and extend its financial horizon to the end […]
Onxeo Launches a Rights Issue to accelerate its R&D programs
This transaction will secure the financing of the strategy and the resources necessary to achieve key clinical milestones until at […]
Publication of the 2020 Annual Financial Report
Paris (France), April 23, 2021 – 7.00 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: […]
Onxeo Reports Full-Year 2020 Financial Results and Provides Business Update
Several major clinical milestones achieved in 2020 by AsiDNA™, including promising initial results in combination with chemotherapy and the launch […]
Onxeo to Present Next-Generation PARP inhibitor, OX401, at the European ESMO-TAT Congress 2020
Paris (France), February 27, 2020 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
Onxeo to Present New Preclinical Data at AACR 2021
Confirming the effect of AsiDNA™ on resistance to KRAS inhibitors Introducing OX400, a new generation of PARP interfering cancer drug […]
B-Smart – Interview of Judith Greciet, CEO of Onxeo
Watch the interview (in French)
Onxeo will publish its annual results on April 21, 2021
The Annual General Meeting will be held on June 10, 2021 Paris (France), March 24, 2021 – 6 pm CET […]
Onxeo Enters Clinical Research Agreement with Institut Curie to Conduct a phase 1b/2 Clinical Trial of AsiDNA™ in combination with radiotherapy for Treatment of High-Grade Glioma Relapse in Children
This study is supported by a grant from the European Fight Kids Cancer program[1] Paris (France), February 4, 2021 […]
Onxeo publishes Letter to Shareholders and provides update on its developments
Paris (France), February 2, 2021 – 9 pm CET – Onxeo S.A. (Euronext Growth: ALONX; Nasdaq First North: ONXEO), a […]
Onxeo Obtains Non-Dilutive Financing of 5 Million Euros in the Form of State Guaranteed Loans
This financing extends the Company’s cash horizon to the 3rd quarter of 2022 Paris (France), January 28, 2021 – […]
2020 – Full-year report on the liquidity contract
2020 Full-year report on the liquidity contract
Onxeo to Attend Key Investor and Scientific Conferences
Paris (France), January 11, 2021 – 7:00 am CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]